Keith Horspool, Ph.D., is Vice President of External Alternative CMC Development (EACD) at Boehringer-Ingelheim Pharmaceuticals, Ridgefield, CT. EACD will be operating as a “biotech within pharma” using a highly flexible integrated network of virtual resources to deliver all CMC requirements for projects, applying alternative development approaches for NCEs and NCE-like new modalities. In particular, the Department seeks to explore, exploit and export “new development” from biotech communities and to access innovative technologies enabling future development. Keith was previously VP of Pharmaceutical Development US, and VP of Material and Analytical Sciences that he established as a new global capability for BI.
Prior to joining BI, Keith worked at Pfizer and Astra Zeneca. He has worked in Pharma for more than 30 years with experience managing preformulation, product development, drug delivery and materials science. Keith has diverse experience with a broad range of delivery systems and various routes of delivery, particularly oral, inhalation and parenteral delivery (including depots). Over the years, he has worked with these various drug delivery technologies from early feasibility through to submission and launch. From a business perspective, he has been involved in simple feasibility contracts, commercial partnerships and technology acquisition. He has a B.Sc. in Pharmacy, and a Ph.D. in Pharmaceutical Chemistry.